Hitting the brakes: Targeting microtubule motors in cancer

British Journal of Cancer

Volumn 113, Issue 5, 2015, Pages 693-698

  Chandrasekaran, Gayathri ^a   Tátrai, Péter ^a   Gergely, Fanni ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

antimitotics; cancer; kinesins; microtubules; mitosis

Indexed keywords

ANTIMITOTIC AGENT; KIFC1 PROTEIN; KINESIN INHIBITOR; MOLECULAR MOTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; KINESIN; TUBULIN MODULATOR;

ARTICLE; CANCER GENETICS; GENOME; GENOMICS; HUMAN; MICROTUBULE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; MITOSIS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; HUMANS; KINESIN; MICROTUBULES; MITOSIS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUBULIN MODULATORS;

EID: 84940794675     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.264     Document Type: Article

References (43)

1. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 14: 130-146.
2. Blangy A, Lane HA, D'herin P, Harper M, Kress M, Nigg EA (1995) Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83: 1159-1169.
3. Brandl MB, Pasquier E, Li F, Beck D, Zhang S, Zhao H, Kavallaris M, Wong ST (2014) Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancer. Mol Oncol 8: 1548-1560.
4. Brito DA, Rieder CL (2006) Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 16: 1194-1200.
5. Brito DA, Rieder CL (2009) The ability to survive mitosis in the presence of microtubule poisons differs significantly between human nontransformed (RPE-1) and cancer (U2OS, HeLa) cells. Cell Motil Cytoskeleton 66: 437-447.
6. Chan JY (2011) A clinical overview of centrosome amplification in human cancers. Int J Biol Sci 7: 1122-1144.
7. Chung V, Heath EI, Schelman WR, Johnson BM, Kirby LC, Lynch KM, Botbyl JD, Lampkin TA, Holen KD (2012) First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemother Pharmacol 69: 733-741.
8. Corson TW, Huang A, Tsao MS, Gallie BL (2005) KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 24: 4741-4753.
9. De S, Cipriano R, Jackson MW, Stark GR (2009) Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res 69: 8035-8042.
10. Firat-Karalar EN, Stearns T (2014) The centriole duplication cycle. Philos Trans R Soc Lond B Biol Sci 369.
11. Gascoigne KE, Taylor SS (2008) Cancer cells display profound intra-and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14: 111-122.
12. Godinho SA, Pellman D (2014) Causes and consequences of centrosome abnormalities in cancer. Philos Trans R Soc Lond B Biol Sci 369.
13. Godinho SA, Picone R, Burute M, Dagher R, Su Y, Leung CT, Polyak K, Brugge JS, Thery M, Pellman D (2014) Oncogene-like induction of cellular invasion from centrosome amplification. Nature 510: 167-171.
14. Gomez HL, Philco M, Pimentel P, Kiyan M, Monsalvo ML, Conlan MG, Saikali KG, Chen MM, Seroogy JJ, Wolff AA, Escandon RD (2012) Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer. Anticancer Drugs 23: 335-341.
15. Guerrero-Preston R, Hadar T, Ostrow KL, Soudry E, Echenique M, Ili-Gangas C, Perez G, Perez J, Brebi-Mieville P, Deschamps J, Morales L, Bayona M, Sidransky D, Matta J (2014) Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity. Oncol Rep 32: 505-512.
16. Hirokawa N, Tanaka Y (2015) Kinesin superfamily proteins (KIFs): various functions and their relevance for important phenomena in life and diseases. Exp Cell Res 334: 16-25.
17. Janssen A, Beerling E, Medema R, Van Rheenen J (2013) Intravital FRET imaging of tumor cell viability and mitosis during chemotherapy. PLoS One 8: e64029.
18. Jordan MA, Toso RJ, Thrower D, Wilson L (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556.
19. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265.
20. Kapitein LC, Peterman EJ, Kwok BH, Kim JH, Kapoor TM, Schmidt CF (2005) The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature 435: 114-118.
21. Lara-Gonzalez P, Westhorpe FG, Taylor SS (2012) The spindle assembly checkpoint. Curr Biol 22: R966-R980.
22. Lonial S, Shah JJ, Zonder J, Bensinger WI, Cohen AD, Kaufman JL, Nooka AK, Weber DM, Hilder B, Rush SA, Ptaszynski A, Walker D, Orlowski RZ (2013) Prolonged survival and improved response rates with ARRY-520 in relapsed/refractory multiple myeloma (RRMM) patients with low a-1 acid glycoprotein (AAG) levels: results from a phase 2 study. Blood 122: 285.
23. Lorusso PM, Goncalves PH, Casetta L, Carter JA, Litwiler K, Roseberry D, Rush S, Schreiber J, Simmons HM, Ptaszynski M, Sausville EA (2015) First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. Invest New Drugs 33: 440-449.
24. Maliga Z, Kapoor TM, Mitchison TJ (2002) Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. Chem Biol 9: 989-996.
25. Malumbres M (2011) Physiological relevance of cell cycle kinases. Physiol Rev 91: 973-1007.
26. Mardin BR, Isokane M, Cosenza MR, Kramer A, Ellenberg J, Fry AM, Schiebel E (2013) EGF-induced centrosome separation promotes mitotic progression and cell survival. Dev Cell 25: 229-240.
27. Marquis L, Tran M, Choi W, Lee IL, Huszar D, Siefker-Radtke A, Dinney C, Mcconkey DJ (2012) p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. Cancer Biol Ther 13: 477-486.
28. Marthiens V, Piel M, Basto R (2012) Never tear us apart - the importance of centrosome clustering. J Cell Sci 125: 3281-3292.
29. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286: 971-974.
30. Mitchison TJ (2012) The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 23: 1-6.
31. Orth JD, Kohler RH, Foijer F, Sorger PK, Weissleder R, Mitchison TJ (2011) Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. Cancer Res 71: 4608-4616.
32. Ping Y, Deng Y, Wang L, Zhang H, Zhang Y, Xu C, Zhao H, Fan H, Yu F, Xiao Y, Li X (2015) Identifying core gene modules in glioblastoma based on multilayer factor-mediated dysfunctional regulatory networks through integrating multi-dimensional genomic data. Nucleic Acids Res 43: 1997-2007.
33. Rath O, Kozielski F (2012) Kinesins and cancer. Nat Rev Cancer 12: 527-539.
34. Salmela AL, Kallio MJ (2013) Mitosis as an anti-cancer drug target. Chromosoma 122: 431-449.
35. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667.
36. Shah JJ, Feng L, Thomas SK, Weber DM, Wang M, Hilder B, Alexanian R, Orlowski RZ (2013) Phase 1 study of the novel kinesin spindle protein inhibitor ARRY-520+carfilzomib in patients with relapsed and/or refractory multiple myeloma. Blood 122: 1982.
37. Shi J, Orth JD, Mitchison T (2008) Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 68: 3269-3276.
38. Singel SM, Cornelius C, Batten K, Fasciani G, Wright WE, Lum L, Shay JW (2013) A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer. Clin Cancer Res 19: 2061-2070.
39. Sivakumar S, Gorbsky GJ (2015) Spatiotemporal regulation of the anaphasepromoting complex in mitosis. Nat Rev Mol Cell Biol 16: 82-94.
40. Tanenbaum ME, Macurek L, Janssen A, Geers EF, Alvarez-Fernandez M, Medema RH (2009) Kif15 cooperates with eg5 to promote bipolar spindle assembly. Curr Biol 19: 1703-1711.
41. Vicente JJ, Wordeman L (2015) Mitosis, microtubule dynamics and the evolution of kinesins. Exp Cell Res 334: 61-69.
42. Wood KW, Lad L, Luo L, Qian X, Knight SD, Nevins N, Brejc K, Sutton D, Gilmartin AG, Chua PR, Desai R, Schauer SP, Mcnulty DE, Annan RS, Belmont LD, Garcia C, Lee Y, Diamond MA, Faucette LF, Giardiniere M, Zhang S, Sun CM, Vidal JD, Lichtsteiner S, Cornwell WD, Greshock JD, Wooster RF, Finer JT, Copeland RA, Huang PS, Morgans Jr. DJ, Dhanak D, Bergnes G, Sakowicz R, Jackson JR (2010) Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci U S A 107: 5839-5844.
43. Yen TJ, Compton DA, Wise D, Zinkowski RP, Brinkley BR, Earnshaw WC, Cleveland DW (1991) CENP-E, a novel human centromere-associated protein required for progression from metaphase to anaphase. EMBO J 10: 1245-1254.